Page last updated: 2024-09-03

imatinib mesylate and Agnogenic Myeloid Metaplasia

imatinib mesylate has been researched along with Agnogenic Myeloid Metaplasia in 40 studies

Research

Studies (40)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	29 (72.50)	29.6817
2010's	8 (20.00)	24.3611
2020's	3 (7.50)	2.80

Authors

Authors	Studies
Atallah, EL; Pettit, K; Radich, J; Rezazadeh, A	1
Hong, J; Li, Q; Ni, J; Sun, G; Xia, R; Zeng, Q; Zhang, Z	1
Decker, M; Ding, L; Lee, Y; Leslie, J; Liu, Q; Martinez-Morentin, L; Wang, G	1
Branford, S; Hiwase, D; Hughes, TP; Shanmuganathan, N	1
Xicoy, B; Zamora, L	1
Fancher, KM; Green, MR; Newton, MD	1
Binda, F; Bucelli, C; Cattaneo, D; Cortelezzi, A; Fermo, E; Gianelli, U; Iurlo, A; Rapezzi, D; Santambrogio, E	1
Aksu, S; Aydin, C; Buyukasik, Y; Demiroglu, H; Eliacik, E; Goker, H; Haznedaroglu, IC; Isik, A; Ozcebe, O; Sayinalp, N; Uner, A	1
Garber, K	1
Gisslinger, H; Haber, P; Kropfmueller, A; Prokop, M; Robibaro, B	1
Hoffman, R; Kiladjian, JJ; Mesa, RA	1
Bakhteeva, TD; Kalinkina, NV; Skliannaia, EV; Taradin, GG; Vatutin, NT	1
Akiyama, T; Fujimi, A; Kato, J; Kikuchi, T; Kogawa, K; Kura, T; Maeda, T; Matsunaga, T; Niitsu, Y; Sato, T; Seki, R; Takahari, D; Takemoto, N; Tanaka, I; Terui, T	1
Hirose, Y; Ito, M; Iwai, M; Kiyoi, H; Naoe, T; Yokozawa, T	1
Cervantes, F; Hernández-Boluda, JC	1
Albitar, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Letvak, L; O'Brien, S; Rios, MB; Salvado, A; Talpaz, M; Thomas, D	1
Akin, C; Brown, M; Dunbar, C; Klion, AD; Law, M; Metcalfe, DD; Noel, P; Nutman, TB; Robyn, J	1
Birgens, H; Bjerrum, OW; Clausen, NT; Hansen, PB; Hasselbalch, HC; Jensen, BA; Ralfkiaer, E; Therkildsen, MH	1
Ishii, Y; Ito, Y; Kuriyama, Y; Ohyashiki, K; Tauchi, T	1
Bueso-Ramos, CE; Cortes, J; Giles, F; Kantarjian, H; Medeiros, LJ; O'Brien, S; Rios, MB; Talpaz, M	1
Consoli, C; Giustolisi, R; Guglielmo, P; Mannino, F; Stagno, F	1
Bastie, JN; Castaigne, S; Cross, NC; Garcia, I; Mahon, FX; Terré, C	1
O'Brien, S; Tefferi, A; Valent, P	1
Bueso-Ramos, CE; Cortes, J; Faderl, S; Giles, F; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Wierda, W	1
Bueso-Ramos, CE; Cortes, J; Giles, F; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J; Talpaz, M	1
Odenike, O; Tefferi, A	1
Arai, Y; Eguchi, M; Eguchi-Ishimae, M; Maki, K; Mitani, K; Nakamura, Y; Sasaki, K; Tadokoro, J; Tokita, K	1
Liu, D; Seiter, K; Yalamanchili, K	1
Bock, O; Buesche, G; Flasshove, M; Henneke, F; Hussein, K; Kreipe, HH; Seegers, A	1
Araki, H; Araki, N; Fujimi, A; Hirayama, Y; Kato, J; Kogawa, K; Matsunaga, T; Murase, K; Niitsu, Y; Takahira, N; Takimoto, R; Terui, T	1
Arai, A; Miyamura, K; Motomura, S; Usui, N; Yokoyama, M	1
Cervantes, F	1
Bock, O; Buesche, G; Frye, B; Gadzicki, D; Ganser, A; Hecker, H; Kreipe, H; Schlegelberger, B; von Neuhoff, N	1
Chen, F; Hou, M; Ji, C; Li, L; Sun, J; Wang, W; Yan, S; Zhang, C; Zhang, M	1
Busuttil, DP	1
Hasselbalch, HC	1
Apfelbeck, U; Beham-Schmid, C; Haas, OA; Höfler, G; Linkesch, W; Sill, H; Tsybrovsky, O	1
Elliott, MA; Mesa, RA; Tefferi, A	1
Hochhaus, A	1
Ansell, SM; Call, TG; Camoriano, JK; Colon-Otero, G; Dewald, GW; Elliott, MA; Gray, LA; Hanson, CA; Kaufmann, SH; Mesa, RA; Pardanani, A; Schroeder, G; Steensma, DP; Tefferi, A	1

Reviews

9 review(s) available for imatinib mesylate and Agnogenic Myeloid Metaplasia

Article	Year
Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to Practice. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2022, Volume: 42 Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Janus Kinase Inhibitors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Primary Myelofibrosis; Protein Kinase Inhibitors	2022
Off-Target Effects of BCR-ABL and JAK2 Inhibitors. American journal of clinical oncology, 2016, Volume: 39, Issue:1 Topics: Aniline Compounds; Antineoplastic Agents; Carbazoles; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Furans; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Harringtonines; Homoharringtonine; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Imidazoles; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Myeloproliferative Disorders; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrazoles; Pyridazines; Pyrimidines; Quinolines; Scleroderma, Systemic; Smallpox; Thrombocythemia, Essential; Tuberculosis, Multidrug-Resistant	2016
The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood, 2011, May-05, Volume: 117, Issue:18 Topics: Apoptosis; Benzamides; Cell Proliferation; Clinical Trials as Topic; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon Type I; Leukemia, Myeloid; Mastocytosis; Neoplastic Stem Cells; Neovascularization, Pathologic; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Pyrimidines; Recombinant Proteins; Thrombocythemia, Essential	2011
[True polycythemia: current views of pathogenesis, diagnostics and treatment]. Klinicheskaia meditsina, 2012, Volume: 90, Issue:8 Topics: Age Factors; Algorithms; Antineoplastic Agents; Aspirin; Benzamides; Combined Modality Therapy; Hematocrit; Hemodilution; Humans; Hydroxyurea; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myeloid, Acute; Mutation; Piperazines; Platelet Aggregation Inhibitors; Polycythemia Vera; Prevalence; Primary Myelofibrosis; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Thrombosis; Treatment Outcome	2012
Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies. Drugs of today (Barcelona, Spain : 1998), 2002, Volume: 38, Issue:9 Topics: Antineoplastic Agents; Benzamides; Biological Availability; Clinical Trials as Topic; Half-Life; Humans; Imatinib Mesylate; Intestinal Absorption; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Pyrimidines	2002
Chronic myelogenous leukemia and myeloproliferative disease. Hematology. American Society of Hematology. Education Program, 2004 Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Piperazines; Primary Myelofibrosis; Pyrimidines	2004
Conventional and new treatment options for myelofibrosis with myeloid metaplasia. Seminars in oncology, 2005, Volume: 32, Issue:4 Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents; Azacitidine; Benzamides; Chronic Disease; Decitabine; Erythropoietin; Humans; Imatinib Mesylate; Piperazines; Primary Myelofibrosis; Pyrimidines; Quinolones; Recombinant Proteins	2005
Myelofibrosis: biology and treatment options. European journal of haematology. Supplementum, 2007, Issue:68 Topics: Benzamides; Chronic Disease; Darbepoetin alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Piperazines; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Recombinant Proteins; Splenectomy; Thalidomide	2007
[Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease]. Deutsche medizinische Wochenschrift (1946), 2002, Mar-01, Volume: 127, Issue:9 Topics: Adult; Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytogenetics; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Lung Neoplasms; Male; Mastocytosis; Multicenter Studies as Topic; Mutation; Neoplasms; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Time Factors	2002

Trials

4 trial(s) available for imatinib mesylate and Agnogenic Myeloid Metaplasia

Article	Year
Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. American journal of hematology, 2003, Volume: 74, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukocytosis; Male; Middle Aged; Piperazines; Polycythemia; Primary Myelofibrosis; Pyrimidines; Thrombocytosis; Treatment Outcome	2003
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer, 2004, Jul-15, Volume: 101, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Primary Myelofibrosis; Pyrimidines; Treatment Outcome	2004
Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia, 2007, Volume: 21, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Bone Marrow; Disease Progression; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Primary Myelofibrosis; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy	2007
Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood, 2002, May-15, Volume: 99, Issue:10 Topics: Adult; Aged; Benzamides; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Myeloid Progenitor Cells; Piperazines; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines	2002

Other Studies

27 other study(ies) available for imatinib mesylate and Agnogenic Myeloid Metaplasia

Article	Year
Marrow fibrosis is an independent predictor of hematological toxicity of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Leukemia & lymphoma, 2020, Volume: 61, Issue:5 Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Primary Myelofibrosis; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome	2020
Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis. Nature cell biology, 2017, Volume: 19, Issue:6 Topics: Animals; Bone Marrow Cells; Cell Differentiation; Cell Lineage; Cell Movement; Cell Proliferation; Disease Models, Animal; Genotype; Hematopoiesis, Extramedullary; Imatinib Mesylate; Mesenchymal Stem Cells; Mice, Inbred C57BL; Mice, Transgenic; Myofibroblasts; Osteogenesis; Phenotype; Primary Myelofibrosis; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Leptin; Signal Transduction; Stem Cell Niche; Thrombopoietin; Time Factors	2017
Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI. Blood advances, 2019, 02-12, Volume: 3, Issue:3 Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Primary Myelofibrosis; Protein Kinase Inhibitors	2019
Current treatment of myeloproliferative neoplasias: three scenarios. Medicina clinica, 2020, 02-28, Volume: 154, Issue:4 Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Niacinamide; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Thrombocythemia, Essential; Time Factors; Withholding Treatment	2020
Imatinib and ruxolitinib association: first experience in two patients. Haematologica, 2014, Volume: 99, Issue:6 Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Pyrazoles; Pyrimidines	2014
Bone marrow fibrosis may be an effective independent predictor of the 'TKI drug response level' in chronic myeloid leukemia. Hematology (Amsterdam, Netherlands), 2015, Volume: 20, Issue:7 Topics: Adult; Aged; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelopoiesis; Primary Myelofibrosis	2015
JAK2 inhibitors: not the next imatinib but researchers see other possibilities. Journal of the National Cancer Institute, 2009, Jul-15, Volume: 101, Issue:14 Topics: Animals; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Piperazines; Point Mutation; Polycythemia Vera; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thrombocytosis	2009
Imatinib, cytokines and interstitial lung disease in a patient with primary myelofibrosis. Annals of hematology, 2010, Volume: 89, Issue:8 Topics: Benzamides; Cytokines; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Male; Middle Aged; Piperazines; Primary Myelofibrosis; Pyrimidines	2010
[Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2002, Volume: 43, Issue:10 Topics: Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Primary Myelofibrosis; Prognosis; Pyrimidines; Remission Induction	2002
Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis. International journal of hematology, 2002, Volume: 76, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Piperazines; Primary Myelofibrosis; Pyrimidines	2002
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer, 2003, Jun-01, Volume: 97, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Pyrimidines; Recurrence	2003
Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood, 2004, Jan-15, Volume: 103, Issue:2 Topics: Adult; Antigens, CD; Benzamides; Bone Marrow; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Middle Aged; Patient Selection; Piperazines; Primary Myelofibrosis; Pyrimidines; Receptors, Interleukin-2	2004
Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis. Leukemia research, 2004, Volume: 28 Suppl 1 Topics: Adult; Benzamides; Growth Substances; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interleukin-5; Male; Piperazines; Primary Myelofibrosis; Pyrimidines; Treatment Outcome	2004
Successful treatment of advanced idiopathic myelofibrosis with imatinib mesylate. European journal of haematology, 2004, Volume: 73, Issue:2 Topics: Benzamides; Cytogenetic Analysis; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Primary Myelofibrosis; Pyrimidines; Treatment Outcome	2004
Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene. Haematologica, 2004, Volume: 89, Issue:10 Topics: Benzamides; Biomarkers; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 5; Disease Progression; Drug Resistance; Enzyme Inhibitors; Gene Rearrangement; Humans; Hydroxyurea; Imatinib Mesylate; Leukocytosis; Male; Middle Aged; Mutant Proteins; Oncogene Proteins, Fusion; Piperazines; Primary Myelofibrosis; Pyrimidines; Splenectomy; Splenomegaly; Thrombocytopenia; Translocation, Genetic; Treatment Failure	2004
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer, 2005, Aug-15, Volume: 104, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Primary Myelofibrosis; Prognosis; Pyrimidines; Survival Analysis	2005
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leukemia & lymphoma, 2005, Volume: 46, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Primary Myelofibrosis; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Treatment Outcome	2005
Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy. Leukemia, 2007, Volume: 21, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 5; Chronic Disease; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Oncogene Proteins, Fusion; Piperazines; Primary Myelofibrosis; Pyrimidines; Transcription, Genetic; Translocation, Genetic	2007
Myelofibrosis with a novel translocation, t(1;3)(q31;q23), and response to imatinib mesylate. Leukemia, 2007, Volume: 21, Issue:3 Topics: Antigens, CD; Benzamides; Bone Marrow Cells; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 3; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Remission Induction; Splenomegaly; Translocation, Genetic	2007
Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood, 2007, May-01, Volume: 109, Issue:9 Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Piperazines; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines; Translocation, Genetic	2007
[Reappearance of t(12;17)-positive primary myelofibrosis following Ph+ CML cell reduction by imatinib]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2007, Volume: 48, Issue:6 Topics: Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 17; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Primary Myelofibrosis; Pyrimidines; Recurrence; Translocation, Genetic	2007
[Physiopathology, diagnosis and treatment of chronic myeloproliferative diseases: discussion]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007, Jul-10, Volume: 96, Issue:7 Topics: Benzamides; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines	2007
A case of Philadelphia-chromosome positive chronic idiopathic myelofibrosis. Leukemia research, 2008, Volume: 32, Issue:4 Topics: Benzamides; Chronic Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Myeloproliferative Disorders; Philadelphia Chromosome; Piperazines; Primary Myelofibrosis; Pyrimidines	2008
Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival. International journal of laboratory hematology, 2008, Volume: 30, Issue:1 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Busulfan; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines; Survivors; Thrombocytopenia	2008
A possible role for STI571 in the treatment of idiopathic myelofibrosis. American journal of hematology, 2001, Volume: 68, Issue:1 Topics: Benzamides; Imatinib Mesylate; Piperazines; Primary Myelofibrosis; Pyrimidines	2001
Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood, 2002, Jan-01, Volume: 99, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow; Enzyme Inhibitors; Erythropoiesis; Female; Granulocytes; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Megakaryocytes; Middle Aged; Piperazines; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction	2002
Adverse events after imatinib mesylate therapy. The New England journal of medicine, 2002, Feb-28, Volume: 346, Issue:9 Topics: Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Middle Aged; Piperazines; Primary Myelofibrosis; Pyrimidines; Radiography; Splenic Rupture; Splenomegaly	2002